Equity Overview
Price & Market Data
Price: $12.30
Daily Change: -$0.107 / 0.87%
Daily Range: $12.00 - $12.49
Market Cap: $268,246,704
Daily Volume: 51,213
Performance Metrics
1 Week: 0.33%
1 Month: -22.12%
3 Months: 25.20%
6 Months: 27.40%
1 Year: -28.58%
YTD: -6.13%
Company Details
Employees: 22
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.